Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well vorinostat works in treating patients with relapsed
or refractory advanced Hodgkin's lymphoma. Vorinostat may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth.